Primary Outcome Measures:
- Number of treatment emergent severe or BG confirmed symptomatic hypoglycaemic episodes during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Number of treatment emergent severe or BG confirmed symptomatic nocturnal hypoglycaemic during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]
- Proportion of subjects with one or more severe hypoglycaemic episodes during the maintenance period [ Time Frame: After 16 weeks of treatment, in each treatment period (Week 16-32 and Week 48-64) ] [ Designated as safety issue: No ]
- Incidence of treatment emergent adverse events [ Time Frame: During 32 weeks of treatment for each treatment period ] [ Designated as safety issue: No ]
- Change from baseline in HbA1c (glycosylated haemoglobin) [ Time Frame: Week 32, Week 64 ] [ Designated as safety issue: No ]
- FPG (fasting plasma glucose) [ Time Frame: Week 32, Week 64 ] [ Designated as safety issue: No ]
